康龙化成(300759) - 2023 Q1 - 季度财报

Financial Performance - The company reported a revenue of CNY 2,723,970,949.97 for Q1 2023, representing a 29.53% increase compared to CNY 2,102,899,933.93 in the same period last year[4] - Net profit attributable to shareholders reached CNY 348,255,328.87, up 39.81% from CNY 249,086,573.60 year-on-year[4] - The adjusted net profit under non-IFRS was CNY 438,339,247.42, reflecting a 20.29% increase from CNY 364,396,375.05 in the previous year[4] - The company achieved a net cash flow from operating activities of CNY 530,139,954.34, which is a 26.89% increase from CNY 417,792,056.81 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 2,723,970,949.97, a 29.5% increase from CNY 2,102,899,933.93 in Q1 2022[23] - Net profit for Q1 2023 was CNY 350,146,873.58, up 47.7% compared to CNY 236,952,176.60 in the same period last year[24] Earnings and Margins - The gross margin for the main business improved to 35.78%, up 2.61 percentage points from 33.17% in the previous year[8] - The basic earnings per share increased to CNY 0.2952, up 40.37% from CNY 0.2103 in the same period last year[4] - Basic earnings per share increased by 40.37% to 0.2952 compared to the same period last year, primarily due to an increase in net profit attributable to shareholders[12] - Diluted earnings per share rose by 40.59% to 0.2951, driven by the same factors as basic earnings[12] Cash Flow and Assets - Cash and cash equivalents increased by 372.6 million RMB, a growth of 37.26% from the beginning of the year[12] - The total current assets as of March 31, 2023, amounted to RMB 6,558,583,630.24, showing a slight increase from RMB 6,536,006,646.99 at the beginning of the year[20] - Cash and cash equivalents increased to RMB 2,055,504,003.16 from RMB 1,497,483,832.74, representing a growth of approximately 37%[20] - The company's long-term equity investments increased to RMB 638,223,819.28 from RMB 629,971,822.34, a rise of about 1.98%[20] - The total cash and cash equivalents at the end of Q1 2023 were CNY 1,990,475,525.11, a decrease from CNY 2,443,525,549.66 at the end of Q1 2022[27] Expenses and Investments - Research and development expenses surged by 93.81% to 76.84 million RMB, reflecting the company's commitment to enhancing R&D capabilities[12] - Management expenses rose by 42.63% to 414.38 million RMB, primarily due to an increase in personnel costs associated with business expansion[12] - Investment income increased significantly by 588.88% to 16.79 million RMB, attributed to higher investment returns from affiliated enterprises[12] - The company reported an investment income of CNY 16,791,039.74, a significant increase from CNY 2,437,442.71 in the previous year[23] Strategic Initiatives - The company continues to focus on a "full-process, integrated, and international" development strategy, with significant contributions from the top 20 global pharmaceutical companies[8] - The company announced a new equity incentive plan for 2023, aimed at aligning employee interests with company performance[18] - The company is actively participating in private equity investments, including a partnership with Wuxi AstraZeneca Zhongjin Venture Capital[17] - The company plans to expand its market presence through strategic investments and potential acquisitions in the biopharmaceutical sector[17] Liabilities and Equity - The total assets at the end of the reporting period were CNY 21,047,569,183.56, reflecting a 2.71% increase from CNY 20,492,557,228.07 at the end of the previous year[4] - Total liabilities rose to CNY 9,772,959,379.20, an increase from CNY 9,652,689,512.90, marking a 1.2% growth year-over-year[22] - The total equity attributable to shareholders of the parent company increased to CNY 10,979,426,501.16, up from CNY 10,548,615,357.20, reflecting a growth of 4.1%[22]